Last reviewed · How we verify
NCT01158066
Association Between NAFLD and Coronary Artery Calcification
NA trial testing CT Cardiac in Coronary Artery Calcification in 120 participants. Status unknown.
1 January 2012
Quick facts
| Lead sponsor | Ziv Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 120 |
| Start date | 1 August 2011 |
| Primary completion | 1 January 2012 |
| Estimated completion | 1 March 2012 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- CT Cardiac
Conditions studied
- Coronary Artery Calcification — all drugs for Coronary Artery Calcification →
Sponsor
Ziv Hospital
Who can join
Adults 45 to 75, any sex, with Coronary Artery Calcification. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Total calcium score measurement
Time frame: 1 month
total calcium score will be measured
Sponsor's own description
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death. Cardiac CT is a reliable non invasive method in demonstrating Coronary Plaques. However the association between coronary artery calcium score (CAC) and NAFLD remains controversial
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01158066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Calcification
Currently open trials in the same condition.
- NCT07340294 — ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate t · NA · active not recruiting
- NCT07400406 — A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries · recruiting
- NCT06181240 — Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) · NA · active not recruiting
- NCT05845424 — High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium · Phase 4 · recruiting
- NCT05346068 — The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial · NA · recruiting
Other Ziv Hospital trials
Trials by the same sponsor.
- NCT05734079 — Impact of Digital Tools on the Quality of Bowel Preparation for Colonoscopy · NA · unknown
- NCT04693013 — Use Of Virtual Reality To Reduce Anxiety And Pain During Repair Of Perineal Laceration And Episiotomy · NA · unknown
- NCT05861661 — Social Cognition in Patients With Anorexia Nervosa- the Study Examines Social Understanding in Patients With AN Via Ques · completed
- NCT04458233 — FNA Guided Ultrasonography Needle Technique Axial Vs Lateral Approach Study · NA · unknown
- NCT03709485 — Evaluation of Gut Microbiome in Patients With Prostate Cancer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01158066 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ziv Hospital
- Last refreshed: 5 April 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01158066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing